PT  - JOURNAL ARTICLE
AU  - Alexander, Lori
ED  - Gross, David
TI  - Favorable Benefit-to-Risk Profile of Everolimus Upheld in Updated Safety Analyses
DP  - 2011 Sep 01
TA  - MD Conference Express
PG  - 16--17
VI  - 11
IP  - 5
4099  - http://mdc.sagepub.com/content/11/5/16.short
4100  - http://mdc.sagepub.com/content/11/5/16.full
AB  - The updated safety results of the RADIANT-2 and −3 Trials have demonstrated a favorable benefit-to-risk profile of everolimus for progressive advanced neuroendocrine tumors. The findings are consistent with those of the initial safety analyses and the known safety profile of the drug in patients with cancer.